Candel Therapeutics Inc (CADL) Stock Price, Quote & News

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic,...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 916 5445

Website: www.candeltx.com

Address:

117 Kendrick Street, Suite 450, Needham, United States

kinosouppp Sep. 13 at 7:36 PM

$CADL I’m honestly scratching my head wondering why there is so much doubt about BLA submission based on the “extremely tight” timeline comment. Obviously anything is possible but the hyper focused analysis is silly when within the same speech Tak made the following points indicating we’re on track:

0 · Reply

Home_Skillet Sep. 13 at 7:32 PM

$CADL for everyone that is worried about a possible delay in the BLA . A administrative or manufacturing delay does not change the fact that the medicine works! I don’t want a delay to happen, but if it does that will be even a better buying opportunity imho.

0 · Reply

claybridge Sep. 13 at 2:10 PM

$CADL people can read for themselves. The "extremely tight" comment was in regard to the comparability study and the final BLA submission can not be filed until that data is ready (and favorable). Read here: https://www.investing.com/news/transcripts/candel-therapeutics-at-cantor-global-healthcare-conference-prostate-cancer-push-93CH-4896805

1 · Reply

drizz Sep. 13 at 1:54 PM

$CADL for the newbies many of us have been on this board for more than a year - me personally more than two - Stu is an obvious short and posts nonsense continuously - there have been several before him posting similar nonsense like DK, Freddie, Dog, etc but eventually they all go by the way side - Stu hasn’t yet gotten the message but my bet is by eoy he will and then he will up and vanish like a fart in the wind ….

1 · Reply

Whiskeyunderthebed Sep. 13 at 1:45 PM

$CADL @claybridge -this is exactly what he said- let's not have you interpret the time line or give false indications.

2 · Reply

GISBlaster98 Sep. 13 at 1:18 PM

$CADL TAM $10B-$15B in US alone, only 77M shares outstanding…and this is a $10.50 stock! I will continue to add to my position big time! Go CADL!

1 · Reply

stu4 Sep. 13 at 12:17 PM

$CADL Caution !!! You are a day late and $4 dollars SHORT ! Hahaha …WARNING : was given at BUS STOP $11 and Fools didn’t listen…or should I say their TAK SEAT BELTS , like TAK himself, wouldn’t release ( real news) and they were trapped , with their bags (holding ) until Bus Stop $9 Stop $10 was under water , already , and no one had life preservers. Well…$9 before $15 , as I once again stated !!! Dilution was leaked from the Board Room , ha ha .

0 · Reply

Greyhound9 Sep. 13 at 12:07 PM

$CADL Good morning, everyone. I’d like to weigh in on all the commotion here. I think you’re all making far too big a deal out of the sale; to me, it’s a storm in a teacup. This was all disclosed back in June, and there’s never a "right" time to actually execute it. Do you really think Manning would have gone ahead with this if it hadn't been appropriate? As someone else here mentioned, doing this right before the BLA filing would have been far more damaging, in my view. PPT has always been transparent and has kept his word every time. He still holds a substantial stake in the company, so there must have been a very good reason for carrying this out now. He could have done it earlier at 13.90—just calculate how much he’s actually missing out on now. I still have full confidence in him and his management team, and any delay—if there even is one—won't last months. Have a great Sunday; sometimes it’s best not to read too much into things—that’s my opinion. ✋🏻

3 · Reply

stu4 Sep. 13 at 11:56 AM

$CADL And the nephew of TAK , doesn’t go back to feb 2025 , when he was here…MUCH HIGHER THAN $9 Hahahaha nice try , 9 months of nothing @drizz

1 · Reply

stu4 Sep. 13 at 11:55 AM

$CADL another minion of TAK , took it up the a$$ !!! Ha ha ha

0 · Reply

Candel Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2026, 8:05 AM EDT - 3 days ago

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

Sep 1, 2026, 4:05 PM EDT - 11 days ago

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 26, 2026, 8:05 AM EDT - 18 days ago

Candel Therapeutics to Present at September Investor Conferences

2026-08-16T13:45:29.000Z - 4 weeks ago

Candel Therapeutics price target raised to $12 from $9 at BofA

Aug 13, 2026, 8:05 AM EDT - 4 weeks ago

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Aug 13, 2026, 8:00 AM EDT - 4 weeks ago

Candel Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 8:00 AM EDT - 4 weeks ago

Candel Therapeutics Quarterly report: Q2 2026

Aug 12, 2026, 12:00 PM EDT - 4 weeks ago

Candel Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 3, 2026, 8:05 AM EDT - 5 weeks ago

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Jul 29, 2026, 8:05 AM EDT - 6 weeks ago

Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston

2026-07-13T09:40:23.000Z - 2 months ago

Candel Therapeutics initiated with a Buy at Stifel

Jul 8, 2026, 4:05 PM EDT - 2 months ago

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 7, 2026, 7:00 AM EDT - 2 months ago

Candel Therapeutics Slides: Corporate presentation

Jun 30, 2026, 8:05 AM EDT - 2 months ago

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Jun 25, 2026, 8:05 AM EDT - 2 months ago

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Jun 23, 2026, 10:00 AM EDT - 2 months ago

Candel Therapeutics Transcript: AGM 2026

Jun 3, 2026, 5:30 PM EDT - 3 months ago

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

2026-06-02T14:27:23.000Z - 3 months ago

Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene

Jun 2, 2026, 8:05 AM EDT - 3 months ago

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

May 20, 2026, 10:00 AM EDT - 3 months ago

Candel Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum

2026-05-18T19:30:09.000Z - 3 months ago

Candel Therapeutics price target raised to $9 from $7 at BofA

May 15, 2026, 4:05 PM EDT - 4 months ago

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

May 15, 2026, 1:00 PM EDT - 4 months ago

Candel Therapeutics Transcript: Study result

May 15, 2026, 1:00 PM EDT - 4 months ago

Candel Therapeutics Slides: Study result

May 15, 2026, 1:00 PM EDT - 4 months ago

Candel Therapeutics Press release: Study result

May 14, 2026, 8:05 AM EDT - 4 months ago

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026, 8:00 AM EDT - 4 months ago

Candel Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 4 months ago

Candel Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 months ago

Candel Therapeutics Slides: Corporate presentation

May 13, 2026, 8:05 AM EDT - 4 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

May 13, 2026, 7:00 AM EDT - 4 months ago

Candel Therapeutics Slides: Corporate presentation

May 4, 2026, 8:05 AM EDT - 4 months ago

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Apr 29, 2026, 8:05 AM EDT - 4 months ago

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Candel Therapeutics Proxy statement: Proxy filing

2026-04-20T10:42:20.000Z - 4 months ago

Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald

Apr 14, 2026, 7:00 AM EDT - 5 months ago

Candel Therapeutics Slides: Corporate presentation

2026-03-18T10:22:07.000Z - 5 months ago

Candel Therapeutics price target raised to $26 from $22 at Citi

2026-03-17T12:22:09.000Z - 6 months ago

Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC

Mar 17, 2026, 8:05 AM EDT - 6 months ago

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Mar 17, 2026, 7:00 AM EDT - 6 months ago

Candel Therapeutics Slides: Corporate presentation

2026-03-13T10:45:12.000Z - 6 months ago

Candel Therapeutics price target lowered to $22 from $24 at Citi

2026-03-12T12:11:41.000Z - 6 months ago

Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year

2026-03-12T12:11:01.000Z - 6 months ago

Candel Therapeutics sees cash runway into 1Q28

Mar 12, 2026, 8:05 AM EDT - 6 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Candel Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Candel Therapeutics Annual report: Q4 2025

Mar 9, 2026, 8:05 AM EDT - 6 months ago

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Mar 3, 2026, 11:50 AM EST - 6 months ago

Candel Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:05 AM EST - 6 months ago

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

2026-02-20T03:25:29.000Z - 6 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:12.000Z - 6 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

Feb 19, 2026, 9:40 PM EST - 6 months ago

Candel Therapeutics Announces Pricing of Public Offering

2026-02-19T22:10:17.000Z - 6 months ago

Candel Therapeutics announces $100M royalty funding agreement

2026-02-19T21:13:42.000Z - 6 months ago

Candel Therapeutics announces $100M common stock offering

Feb 19, 2026, 4:05 PM EST - 6 months ago

Candel Therapeutics Announces Proposed $100 Million Public Offering

Feb 19, 2026, 4:01 PM EST - 6 months ago

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Feb 11, 2026, 8:05 AM EST - 7 months ago

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Dec 10, 2025, 7:00 AM EST - 9 months ago

Candel Therapeutics Slides: Corporate Presentation

Dec 5, 2025, 11:00 AM EST - 9 months ago

Candel Therapeutics Transcript: R&D Day 2025

Dec 5, 2025, 11:00 AM EST - 9 months ago

Candel Therapeutics Press release: FY 2025

Nov 18, 2025, 3:00 AM EST - 9 months ago

Candel Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 4:05 PM EST - 9 months ago

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

2025-11-14T11:40:57.000Z - 10 months ago

Candel Therapeutics price target lowered to $24 from $25 at Citi

2025-11-13T13:31:40.000Z - 10 months ago

Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year

Nov 13, 2025, 8:25 AM EST - 10 months ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Nov 13, 2025, 8:00 AM EST - 10 months ago

Candel Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Candel Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Candel Therapeutics Slides: Corporate Presentation

2025-11-04T14:10:59.000Z - 10 months ago

Candel Therapeutics announces it will deliver three presentations at SITC

Nov 4, 2025, 9:00 AM EST - 10 months ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 3, 2025, 8:05 AM EST - 10 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

2025-10-28T11:21:24.000Z - 10 months ago

Candel initiated with an Overweight at Stephens on differentiated pipeline

2025-10-27T20:35:14.000Z - 10 months ago

Candel Therapeutics initiated with an Overweight at Stephens

2025-10-21T10:40:56.000Z - 10 months ago

Candel Therapeutics initiated with an Outperform at LifeSci Capital

Oct 16, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 14, 2025, 8:10 AM EDT - 11 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 11 months ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Oct 14, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 3, 2025, 9:05 AM EDT - 11 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Sep 29, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 12 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 5, 2025, 7:00 AM EDT - 1 year ago

Candel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:00 AM EDT - 1 year ago

Candel Therapeutics Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Aug 28, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 14, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Registration statement: Registration Filing

Aug 13, 2025, 2:00 PM EDT - 1 year ago

Candel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Jul 30, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 9, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jun 24, 2025, 9:05 AM EDT - 1 year ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 23, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 6, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 27, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 22, 2025, 5:05 PM EDT - 1 year ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 14, 2025, 7:20 PM EDT - 1 year ago

Candel Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

kinosouppp Sep. 13 at 7:36 PM

0 · Reply

Home_Skillet Sep. 13 at 7:32 PM

0 · Reply

claybridge Sep. 13 at 2:10 PM

1 · Reply

drizz Sep. 13 at 1:54 PM

1 · Reply

Whiskeyunderthebed Sep. 13 at 1:45 PM

$CADL @claybridge -this is exactly what he said- let's not have you interpret the time line or give false indications.

2 · Reply

GISBlaster98 Sep. 13 at 1:18 PM

$CADL TAM $10B-$15B in US alone, only 77M shares outstanding…and this is a $10.50 stock! I will continue to add to my position big time! Go CADL!

1 · Reply

stu4 Sep. 13 at 12:17 PM

0 · Reply

Greyhound9 Sep. 13 at 12:07 PM

3 · Reply

stu4 Sep. 13 at 11:56 AM

$CADL And the nephew of TAK , doesn’t go back to feb 2025 , when he was here…MUCH HIGHER THAN $9 Hahahaha nice try , 9 months of nothing @drizz

1 · Reply

stu4 Sep. 13 at 11:55 AM

$CADL another minion of TAK , took it up the a$$ !!! Ha ha ha

0 · Reply

badprecog Sep. 13 at 10:18 AM

$CADL Tak was criticized for the 2.5 years post p3 readout to file the BLA. The comment about the schedule being tight was him just explaining that they have been working dilligently the whole time and there is no wasted effort. It’s a very bad short thesis to think he is implying a delay. They have been working on this time table for 2.5 years and 3 months out they PR with the appointment of the new board of director a filing this year in the Q4. So by now he should know if a delay is likely coming and he would not put that in the pr if he thought it was.

1 · Reply

stu4 Sep. 13 at 2:15 AM

$CADL gave most here a reality check, of the TAK and his misgivings as CEO ..and more infantry to get a BLA done , cause no one will touch him in the BP world !!! A scapegoat will surface …hahaa.Zimmerman or Sims

2 · Reply

stu4 Sep. 13 at 2:13 AM

$CADL and you were ther , right !!!! Hahah Another load of siht …nice pump of the imbecile

1 · Reply

stu4 Sep. 13 at 2:11 AM

$CADL here at CADL , YES ..you will ..take it up the a$$

1 · Reply

stu4 Sep. 13 at 2:11 AM

$CADL This is a load of siht ..@trendsetter20

1 · Reply

stu4 Sep. 13 at 2:08 AM

$CADL Lucky ???? are you on drugs ??? Lucky is short since $14 and winning !!!! Under $5 is lucky , since you still can buy this oos on margin Hahahahaha @Bmann707

1 · Reply

stu4 Sep. 13 at 2:06 AM

$CADL you pump clown ..a fund said Fcuk you , Friday Stop the pump …@Spywest … Who cares what the CEO gets as a pkg, the street just spoke Friday …he sucks

0 · Reply

stu4 Sep. 13 at 2:04 AM

$CADL Losers ..I was over at a real Scientist and business man’s creation ..ALNY !!!! picked up 7 points or 7K , in 24 hours , hahahaa , you losers No winners at CADL …haven’t been for 19 months

1 · Reply

stu4 Sep. 13 at 2:01 AM

$CADL read it and weep @John_morrris !!!

0 · Reply

stu4 Sep. 13 at 2:00 AM

$CADL …call it …I haven’t been wrong in 19 months running !!! … Vernacular changed in a press release and TAK is adding bodies that deal with the FDA as a profession, he is a mere university hack, that GSK gave a shot to., and he blew it They merged the company to end the CADH BURN OF TAK , nothing came off the bench !!! You’ll see. !!! I called $11 before $15 , I called $9 Friday before it even hit $10 The street is done with his bull siht

1 · Reply

claybridge Sep. 12 at 10:52 PM

$CADL not gonna lie, I was a tad panicked last week and I still am with regard to a possible BLA delay. I don't think you tell investors things are "extremely tight" with regard to a quickly approaching BLA submission unless you're prepping them for a possible delay. Investors don't care how tight it is or isn't, we just care whether or not they're going to meet the deadline that has been advertised for 2 friggin years now. Anywho, I thought I'd share a comp between XBI and CADL, each on their own price scale so we can assess directionality. CADL is much higher beta, so will always move much more +/- as a %. That's not helpful and why I'm focusing on directionality. Regardless of Tak's sale or the deadline "being tight", most of the selling pressure likely was related to XBI's sell-off IMO.

4 · Reply

Matador44 Sep. 12 at 5:13 PM

$CADL

0 · Reply

Market Cap	806.89M
Revenue (ttm)	0.00
Net Income (ttm)	-38.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.38

Volume	3,596,200
Avg Vol	1,283,702
Day's Range	N/A - N/A
Shares Out	76.52M
Stochastic %K	19%
Beta	-0.48
Analysts	Strong Sell
Price Target	$21.00